Devyser Diagnostics (DVYSR) Q3 2026 earnings summary

Executive summary

• Q3 net sales rose 5.8% YoY to SEK 59.7m; FX-adjusted growth was 5.7%. A major distributor’s inventory correction continued to constrain sales.

• Q3 EBIT improved to SEK 7.1m from SEK 1.3m; net profit was SEK 7.3m versus a SEK 2.8m loss, and operating cash flow was SEK 22.0m.

• Underlying demand remained strong, particularly in direct markets; distributor sales are expected to remain weaker through Q4 before normalizing from 2027.

Financial highlights

• 9M net sales were SEK 181.7m, up 1.8% reported and 4.9% FX-adjusted; 9M gross profit was SEK 145.8m versus SEK 144.7m.

• 9M EBIT was SEK 10.2m versus a SEK 8.0m loss; net profit was SEK 11.8m versus a SEK 22.0m loss, and EPS was SEK 0.70 versus a SEK 1.33 loss.

• Q3 EBITDA was SEK 14.7m with a 24.6% margin, versus SEK 8.1m and 14.4%; Q3 EPS was SEK 0.43 versus a SEK 0.17 loss.

• Q3 selling expenses fell to SEK 23.6m from SEK 26.2m; 9M operating expenses declined to SEK 136.5m from SEK 152.3m, mainly from cost-efficiency measures.

• Operating cash flow was SEK 22.0m versus negative SEK 0.5m; liquidity was SEK 88.7m versus SEK 84.9m.

Outlook and guidance

• Distributor sales are expected to remain weaker through Q4 due to inventory reduction, with a gradual return to more normal levels during 2027; quarterly timing remains uncertain.

• The aim is profitable growth faster than the market, prioritizing the US and Western Europe while maintaining cost efficiency.

• A MolDx decision is targeted before year-end, subject to review timing; FDA work, commercialization preparations, channel strategy and IVDR certification continue.

• Reagent rental agreements are expected to contribute more visibly to growth in 2027; sales may begin after system installation.